ZA201404732B - Leukotriene b4 antagonist compound - Google Patents

Leukotriene b4 antagonist compound

Info

Publication number
ZA201404732B
ZA201404732B ZA2014/04732A ZA201404732A ZA201404732B ZA 201404732 B ZA201404732 B ZA 201404732B ZA 2014/04732 A ZA2014/04732 A ZA 2014/04732A ZA 201404732 A ZA201404732 A ZA 201404732A ZA 201404732 B ZA201404732 B ZA 201404732B
Authority
ZA
South Africa
Prior art keywords
leukotriene
antagonist compound
antagonist
compound
Prior art date
Application number
ZA2014/04732A
Other languages
English (en)
Inventor
Douglas Richard Stack
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA201404732B publication Critical patent/ZA201404732B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2014/04732A 2012-01-10 2014-06-26 Leukotriene b4 antagonist compound ZA201404732B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584975P 2012-01-10 2012-01-10
US201261585799P 2012-01-12 2012-01-12
PCT/US2013/020195 WO2013106238A1 (en) 2012-01-10 2013-01-04 Leukotriene b4 antagonist compound

Publications (1)

Publication Number Publication Date
ZA201404732B true ZA201404732B (en) 2015-11-25

Family

ID=47604162

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/04732A ZA201404732B (en) 2012-01-10 2014-06-26 Leukotriene b4 antagonist compound

Country Status (14)

Country Link
US (1) US9187411B2 (enExample)
EP (1) EP2802557B1 (enExample)
JP (1) JP2015509917A (enExample)
KR (1) KR20140099546A (enExample)
CN (1) CN104011012B (enExample)
AU (1) AU2013208260A1 (enExample)
BR (1) BR112014016450A2 (enExample)
CA (1) CA2857521C (enExample)
EA (1) EA023067B1 (enExample)
ES (1) ES2571452T3 (enExample)
IN (1) IN2014MN01014A (enExample)
MX (1) MX2014008452A (enExample)
WO (1) WO2013106238A1 (enExample)
ZA (1) ZA201404732B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PH30449A (en) 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
CN1035001C (zh) * 1993-01-02 1997-05-28 伊莱利利公司 取代的苯基苯酚基白三烯拮抗物
WO1996036347A1 (en) 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
WO1998042346A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
CN1237968C (zh) 2000-05-09 2006-01-25 克赖顿大学 抑制癌细胞的增殖和诱导其凋亡的方法
EP1286982A2 (en) * 2000-06-02 2003-03-05 Eli Lilly & Company Process for the preparation of benzoyl substituted bicylic compounds and chiral bnezopyran derivatives
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物

Also Published As

Publication number Publication date
US9187411B2 (en) 2015-11-17
EP2802557B1 (en) 2016-04-06
JP2015509917A (ja) 2015-04-02
CA2857521A1 (en) 2013-07-18
CA2857521C (en) 2016-03-01
KR20140099546A (ko) 2014-08-12
EA201491099A1 (ru) 2014-11-28
AU2013208260A1 (en) 2014-06-05
CN104011012A (zh) 2014-08-27
EP2802557A1 (en) 2014-11-19
IN2014MN01014A (enExample) 2015-07-03
CN104011012B (zh) 2016-01-20
MX2014008452A (es) 2014-08-27
WO2013106238A1 (en) 2013-07-18
US20140343151A1 (en) 2014-11-20
ES2571452T3 (es) 2016-05-25
BR112014016450A2 (pt) 2019-09-24
EA023067B1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
IL235986A0 (en) Tetrahydropyrazolopyrimidine compounds
GB201209138D0 (en) Compounds
ZA201504980B (en) Heterocyclic compound
GB201214750D0 (en) Compounds
EP2832734A4 (en) HETEROCYCLIC COMPOUND
AU344048S (en) Barrier
GB201220843D0 (en) Compound
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
IL233434A0 (en) skirt barrier
ZA201406322B (en) Azaheterocyclic compounds
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
AU344047S (en) Barrier
GB201209096D0 (en) Compounds
AU344046S (en) Barrier
AU344050S (en) Barrier
AU344045S (en) Barrier
GB201219820D0 (en) Compounds
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
AU344049S (en) Barrier
GB201217310D0 (en) Compounds
GB201216448D0 (en) Compound
GB201222716D0 (en) Compound
GB201214106D0 (en) Immunomodulatory compounds